WASHINGTON (Reuters) - The divided U.S. Congress after the November midterm elections undermines pharmaceutical companies who want to weaken a new law that allows the government to negotiate drug prices, Republican strategists, policy experts and pharmaceutical executives say
Scooped by
Occupy Hades
onto Operation Deimos November 18, 2022 3:41 PM
|